Diagnostics Special Report: Non-invasion of the body snatchers
15 October 2015
Despite the rapid advances in identifying and understanding the nature of driver mutations and resistance markers in various cancers—information that is going a long way to individualizing patient care—the challenge of fully characterizing a cancer within a single patient remains significant. Even in situations where a solid tumor exists, it is not always possible to obtain a tissue biopsy due to clinical inaccessibility or unacceptable risks to patient safety.
Is Google a competitor or partner to Big Pharma? Roche's CEO doesn't know, yet
15 October 2015
The advance of Google ($GOOG) and other tech firms into life sciences has given drug developers a new source of partners with complementary skills, but also raised an awkward question: Long term, are these companies allies or rivals? For Roche ($RHHBY) CEO Severin Schwan, the answer is still unclear.
Hong Kong's gray market draws mainland Chinese looking for lifesaving meds they can't afford at home
15 October 2015
Duties and distribution costs have made top-tier drugs in China among the most expensive in the world. If they can be found cheaper, chances are they are counterfeit. As a result, a thriving gray market in Hong Kong is drawing tourists from the mainland looking to get drugs like Gilead Sciences' hep C med Sovaldi or Roche's breast cancer drug Herceptin, often without a prescription.
The Way We're Testing Antibiotics Is All Wrong
15 October 2015
For 50 years, hospitals have used a single test to decide how to treat the most stubborn infections. But according to a growing body of research, that test is now wrong more often than we'd thought. All because of the rise of antibiotic-resistant bacteria that behave one way in lab tests and another way in the human body.
European investor snatches up DNA test maker DNA Diagnostics for $118M
15 October 2015
DNA testing outfit DNA Diagnostics is selling out to European healthcare investor GHO Capital for €104 million ($118 million), allowing GHO to cash in on the genetic testing market and expand its international footprint while increasing DDC's global reach.
3Q venture capital decreases, but there's a silver lining
14 October 2015
When you compare third quarter investments in private U.S companies to the rest of 2015, it doesn't look pretty. Just 39 companies tracked by BioWorld Snapshots garnered the attention of venture capitalists in the third quarter compared to 53 in the first quarter and 50 in the second quarter.
Jim Blair Shares Insights on Future Direction of Genomics with Investor Business Daily
14 October 2015
Jim Blair, Ph.D., a founder of Domain Associates has seen genomics grow from its infancy into the rapidly developing space it is today. In 1981, as managing director at Rothschild, Inc., Dr. Blair invested funds managed by his firm in the start-up financing for Applied Biosystems, developers of the gene sequencers later used in the Human Genome Project.
Pharma's digital desires thwarted by clunky organizations, lack of skilled employees
14 October 2015
While pharma lags in some areas of digital adoption, it's generally not for lack of ambition. It's what market researcher eConsultancy called healthcare companies' "fits and starts" in their embrace of digital technology, in a recent study done with Ogilvy CommonHealth and OgilvyRED.
Precision medicine in the real world
13 October 2015
In a perfect world, doctors would have the diagnostics to determine the right treatment for each patient at the right dose and the right time. It would be called precision medicine.
British docs weigh in on pharma, and it's no better than most U.S. opinions
13 October 2015
Pharma is snookered in England too. British healthcare providers (HCPs) are just as unhappy with drugmakers as everyone else. The newest survey finds that more than 40% of U.K. doctors view the industry negatively, reports healthcare data intelligence firm Binley's.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024